Published in Blood on December 18, 2008
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood (2011) 2.09
Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget (2015) 1.58
miR-17-92 cluster: ups and downs in cancer and aging. Biogerontology (2010) 1.32
p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep (2011) 1.25
Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood (2009) 1.21
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 1.18
An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer (2011) 1.05
cir-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway. PLoS One (2015) 0.96
Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci (2013) 0.93
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
Prioritizing human cancer microRNAs based on genes' functional consistency between microRNA and cancer. Nucleic Acids Res (2011) 0.88
p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood (2009) 0.84
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene (2014) 0.83
Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia. Epigenomics (2010) 0.82
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer. Oncotarget (2016) 0.82
MiR-106b exhibits an anti-angiogenic function by inhibiting STAT3 expression in endothelial cells. Lipids Health Dis (2016) 0.81
Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma. Int J Clin Exp Med (2014) 0.81
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clin Cancer Res (2016) 0.81
An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model. Oncotarget (2016) 0.81
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs (2011) 0.80
Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway. PLoS One (2015) 0.79
MicroRNA activity in B lymphocytes. Methods Mol Biol (2010) 0.76
Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.76
Differential Sensitivity of Target Genes to Translational Repression by miR-17~92. PLoS Genet (2017) 0.75
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer (2016) 0.75
Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood (2016) 0.75
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
Genome-wide map of nucleosome acetylation and methylation in yeast. Cell (2005) 15.08
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol (2003) 9.90
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Processing of intronic microRNAs. EMBO J (2007) 6.32
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem (2003) 2.69
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood (2004) 2.37
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ (2005) 1.90
Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem (2000) 1.88
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia (2007) 1.73
The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ (2006) 1.72
Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs (2007) 1.60
miRNAs and their potential for use against cancer and other diseases. Future Oncol (2007) 1.47
p73, a sophisticated p53 family member in the cancer world. Cancer Sci (2005) 1.39
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res (2008) 1.23
Regulation of Geminin and Cdt1 expression by E2F transcription factors. Oncogene (2004) 1.22
Cloning and characterization of human MCM7 promoter. Gene (1998) 1.18
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ (2003) 1.08
New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun (2005) 1.02
The role of p73 in hematological malignancies. Leukemia (2006) 1.00
Efficient gene transfer in CLL by mRNA electroporation. Leukemia (2007) 0.96
Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol (2007) 0.91
p73, the "assistant" guardian of the genome? Ann N Y Acad Sci (2003) 0.91
Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia (2002) 0.87
Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia (2006) 0.85
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell (2008) 4.01
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2008) 3.19
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood (2002) 3.03
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99
MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res (2008) 2.97
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome (2006) 2.64